UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): January 6, 2020

E-QURE CORP.

(Exact Name of Registrant as Specified in its Charter)

Commission File No.: 000-54862

Delaware		47-1691054
(State or other Jurisdiction of Incorporation or Organization)		(I.R.S. Employer Identification No.)

20 West 64th Street, Suite 39G, New York, NY		10023
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, including area code: + (972) 54-422-7777

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(gb) of the Act: None

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, par value $0.00001		EQUR		OTCQB

Item 8.01 Other Events.

~~E-Qure~~On ~~Corp.~~March 4, a2020, ~~Delaware~~the ~~corporation,~~U.S. ~~OTCQB:~~Securities ~~EQUR~~and Exchange Commission (the “~~Company~~SEC”), aissued ~~medical~~an ~~device~~order ~~Company,~~(Release ~~reported~~No. ~~today~~34-88318) under Section 36 of the ~~following material~~Securities ~~updates~~Exchange ~~regarding~~Act ~~Bioelectrical~~of ~~Signal~~1934, ~~Therapy~~as ~~device~~amended (the “~~BST~~Exchange ~~Device~~Act”), ~~developed~~granting ~~for~~exemptions ~~the~~from ~~treatment~~specified provisions of ~~wounds via~~the ~~electrical~~Exchange ~~stimulation~~Act and certain rules thereunder. On March 25, ~~which~~2020, isthe ~~believed~~order was modified and superseded by a new SEC order (Release No. 34-88465) that provides conditional relief to public companies with respect to their filing requirements as a result inof ~~accelerated~~the ~~wound~~recent ~~healing~~coronavirus by(“COVID-19”) ~~imitating~~outbreak (the ~~natural~~“SEC ~~electrical~~Order”). ~~current~~E-Qure Corp., a Delaware ~~that~~corporation ~~occurs~~(the in“Company”) ~~injured~~will ~~skin~~be relying on the ~~human~~SEC ~~body.~~Order ~~Our~~related ~~BST~~to ~~Device~~the ~~stimulates~~timing ~~renewed~~of ~~blood~~the ~~flow~~filing ~~and~~of ~~oxygen~~its inQuarterly Report ~~order~~on toForm ~~induce~~10-Q ~~local cell~~for ~~regeneration~~the ~~and~~quarter ~~therefore~~ended ~~promote~~March ~~wound~~31, ~~healing.~~2020 (the “Quarterly Report”) due to circumstances related to the COVID-19 outbreak.

1.As ~~The~~a result of COVID-19, the Company has been ~~granted~~following ~~with~~ the ~~Helsinki~~recommendations ~~committee~~of ~~approval~~health ofauthorities ~~Clalit~~to ~~Health~~minimize ~~Services~~exposure ~~Organization,~~risk ~~Israel’s~~for ~~largest~~our ~~HMO,~~employees ~~and~~for the ~~Israeli~~past ~~Ministry~~several ofweeks, ~~Health~~including ~~(MOH)~~allowing employees to ~~launch~~work aremotely ~~Randomized~~to ~~Control~~the ~~Study~~extent ~~(RCT)~~possible. onThis ~~60-100~~has ~~patients in order to assess~~impacted the ~~efficacy~~normal ofinteractions ~~the~~and ~~BST~~collaborations ~~Device~~among onour ~~diabetic~~accounting ~~foot~~and ~~patients.~~financial ~~The~~reporting ~~study~~personnel ~~will~~involved bewith ~~performed~~the incompletion of ~~3-5~~the ~~sites~~quarterly ~~including~~review ~~leading clinics~~ and ~~hospitals~~ inpreparation ~~Israel.~~of ~~The~~the ~~Company~~Quarterly ~~intends~~Report. toThis ~~enroll~~is ~~the~~impacting ~~first patients to~~ the ~~study~~timing ~~during~~of the ~~next~~review, ~~2-3~~preparation ~~weeks~~ and ~~expects the trial~~completion toof beour ~~conducted~~financial statements for ~~12-18~~the ~~months~~first ~~until~~quarter ~~completion~~of 2020.

2.Although ~~The~~the Company ~~has~~can ~~concluded~~provide ano ~~35-wound~~assurance, ~~one~~the ~~arm~~Company ~~clinical~~does ~~pilot,~~plan ~~treating~~to ~~recalcitrant~~file ~~wounds~~the inQuarterly aReport ~~leading~~on/or ~~wound~~about ~~clinic~~May in29, ~~Tel Aviv Israel~~but, ~~with~~in ~~78%~~any ofevent, no ~~the~~later ~~treated~~than ~~wounds~~June ~~completely~~29, ~~healed~~2020, ~~within~~which 20is ~~weeks~~45 ~~(Avg.~~days ~~wound~~from ~~duration at~~ the ~~base~~Quarterly ~~was~~Report’s 8original ~~months)~~filing ~~and~~deadline ~~an additional 16%~~ of ~~the~~May ~~treated~~15, ~~wounds~~2020. ~~reaching~~If ~~wound~~the Quarterly ~~area~~Report ~~reduction~~is offiled ~~greater~~by ~~than~~June ~~75%.~~29, ~~Only~~2020, 6%the offiling ~~the~~will ~~patients~~be ~~had~~deemed notimely ~~substantial positive~~by ~~clinical~~the ~~effect~~SEC.

3.Cautionary ~~The~~Note ~~Company~~Regarding ~~recently~~Forward-Looking ~~filed a provisional patent with United States Patent and Trademark Office for the purpose of protecting the main features of our proprietary unique electrical healing signal BST Device.~~Statements

4.This ~~The~~Current ~~Company’s~~Report ~~distributor~~on inForm ~~Colombia,~~8-K ~~TekMedica~~contains ~~SAS,~~statements ~~has~~as ~~successfully~~to ~~concluded~~the aCompany’s ~~clinical~~beliefs ~~pilot~~and ~~study~~expectations atas to the ~~Hospital~~effects that the COVID-19 depandemic lamay ~~Samaritana~~have inon ~~Bogota~~our business, ~~Colombia.~~which ~~Starting~~are inforward-looking ~~January~~statements. ~~2020,~~These ~~Colsanitas,~~forward-looking astatements ~~leading~~are ~~Colombian~~subject ~~HMO/Health~~to ~~insurance provider~~risks and ~~operator~~uncertainties ofthat ~~comprehensive~~could ~~healthcare~~cause ~~services~~actual inresults ~~Colombia~~to ~~and~~differ amaterially ~~member~~from of the ~~Sanitas~~statements ~~group~~made. ~~worldwide,~~These ~~will~~risks ~~commence~~and ~~a clinical~~uncertainties ~~pilot~~include, ~~study~~but ~~which~~are isnot ~~expected~~limited to, bethose ~~concluded~~described byin the ~~end~~risk offactor ~~the~~above. ~~first~~Except ~~half~~as ofrequired ~~2020.~~by Iflaw, ~~positive~~the ~~results~~Company ~~are~~does ~~achieved,~~not ~~similar~~undertake toany ~~those~~obligation ~~achieved~~to inrelease ~~the~~publicly ~~Tel~~any ~~Aviv~~revisions ~~clinical~~to ~~trials,~~forward-looking ~~the~~statements ~~Company~~made ~~believes~~by ~~that~~ it ~~will~~to ~~contribute~~reflect toevents ~~the~~or ~~penetration~~circumstances ofoccurring after the ~~BST device~~date ~~treatment~~hereof ~~with~~or ~~Colsanitas~~the ~~health~~occurrence ~~services~~of inunanticipated ~~Colombia~~events.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

E-QURE CORP.
	/s/: Ohad Goren
Name:	Ohad Goren
Title:	Chief Executive Officer
Dated:	~~January~~May 2120, 2020

Filing Compare · E-Qure Corp.